Financhill is a comprehensive financial analysis platform that provides stock analysis, market data, investment tools, and educational resources to help investors make informed decisions.

How do I get started with Financhill?

You can start by creating a free account, exploring our stock analysis tools, setting up a watchlist, or trying our 7-day trial for full access to all premium features.

What features does Financhill offer?

Financhill offers stock analysis, technical charts, fundamental data, earnings information, dividend tracking, portfolio management, market screening tools, and educational resources.

What are 10K annual reports?

10K reports are comprehensive annual reports filed by public companies with the SEC, containing detailed financial statements, business operations, risk factors, and management discussion.

How often are annual reports updated?

Annual reports are typically filed once per year, usually within 60-90 days after the company's fiscal year end. We update our database as soon as new reports become available.

How do I analyze MTD stock?

Use our comprehensive analysis tools including technical charts, fundamental metrics, earnings data, and Stock Score to evaluate MTD investment potential.

What is MTD stock price today?

Get real-time MTD stock price, historical data, and price charts on Financhill. Track MTD performance with our advanced analysis tools.

Is MTD a good investment?

Evaluate MTD investment potential using our Stock Score, fundamental analysis, technical indicators, and earnings data. Consider your risk tolerance and investment goals.

How to buy MTD stock?

To buy MTD stock, open a brokerage account, research the company using our analysis tools, and place your order through your broker. Always do your own research before investing.

What is the market cap of MTD?

View detailed market capitalization data and company valuation metrics for MTD on our comprehensive analysis page.

What is the P/E ratio of MTD?

Use our fundamental analysis tools to view MTD P/E ratio and compare valuation metrics with industry peers.

What are MTD earnings?

View MTD earnings data, quarterly results, revenue growth, and profit margins on our comprehensive earnings analysis page. Track earnings trends and analyst estimates.

Back

Mettler-Toledo International, Inc. 10K Form

Buy

MTD
Mettler-Toledo International, Inc.

Last Price:

$1,364.26

Seasonality Move:

3.14%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive MTD News And Ratings

See the #1 stock for the next 7 days that we like better than MTD

MTD Financial Statistics

Sales & Book Value

Annual Sales:	$4B
Cash Flow:	$184.1M
Price / Cash Flow:	33.54
Annual Sales:	$-1.16
Price / Book:	0

Profitability

EPS (TTM):	42.11760
Net Income (TTM):	$869.2M
Gross Margin:	$2.3B
Return on Equity:	0%
Return on Assets:	25.4%

Mettler-Toledo International, Inc. Earnings Forecast

Key Mettler-Toledo International, Inc. Financial Ratios

The Gross Profit Margin over the past 29 years for MTD is 57.52%.
The Selling, General & Administrative Expenses for MTD have been equal to 24.79% of Gross Profit Margin.
The Research & Development expenses have been 4.95% of Revenue.
The Interest Expense is 8.84% of Operating Income.
The Net Earning history of MTD is 21.59% of Total Revenues.
Per Share Earnings over the last 29 years have been positive in 25 years.

Mettler-Toledo International, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange:	NYSE
Industry:	Life Sciences Tools & Services
Sector:	Health Care
Current Symbol:	MTD
CUSIP:	592688
Website:	mt.com

Debt

Debt-to-Equity Ratio:	-95.84
Current Ratio:	1.14
Quick Ratio:	0.72

Price-to-Earnings

Trailing P/E Ratio:	32.74
Forward P/E Ratio:	26.92

MTD Technical Analysis vs Fundamental Analysis

Buy

Mettler-Toledo International, Inc. (MTD) is a Buy

Is Mettler-Toledo International, Inc. a Buy or a Sell?

Mettler-Toledo International, Inc. stock is rated a Buy

The current Mettler-Toledo International, Inc. [MTD] share price is $1,376.53. The Score for MTD is 59, which is 18% above its historic median score of 50, and infers lower risk than normal.